IDO1 and ovarian carcinoma: GBP1 protects ovarian cancer cells from paclitaxel by associating with beta-tubulin, altering cytoskeletal dynamics to sequester the drug within the microtubule network, and partnering with IDO-1 to reduce apoptosis—a dual shield against cell death that enhances chemotherapeutic resistance [19,22,55].